Cargando…
Therapeutic potential of induced iron depletion using iron chelators in Covid-19
Ferritin, which includes twenty-four light and heavy chains in varying proportions in different tissues, is primarily responsible for maintaining the body's iron metabolism. Its normal value is between 10 and 200 ngmL(−1) in men and between 30 and 300 ngmL(−1) in women. Iron is delivered to the...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666385/ https://www.ncbi.nlm.nih.gov/pubmed/34924800 http://dx.doi.org/10.1016/j.sjbs.2021.11.061 |
_version_ | 1784614197733097472 |
---|---|
author | Poonkuzhi Naseef, Punnoth Elayadeth-Meethal, Muhammed Mohammed Salim, K.T. Anjana, A Muhas, C Abdul Vajid, K. Saheer Kuruniyan, Mohamed |
author_facet | Poonkuzhi Naseef, Punnoth Elayadeth-Meethal, Muhammed Mohammed Salim, K.T. Anjana, A Muhas, C Abdul Vajid, K. Saheer Kuruniyan, Mohamed |
author_sort | Poonkuzhi Naseef, Punnoth |
collection | PubMed |
description | Ferritin, which includes twenty-four light and heavy chains in varying proportions in different tissues, is primarily responsible for maintaining the body's iron metabolism. Its normal value is between 10 and 200 ngmL(−1) in men and between 30 and 300 ngmL(−1) in women. Iron is delivered to the tissue via them, and they act as immunomodulators, signaling molecules, and inflammatory markers. When ferritin level exceeds 1000 µgL(-1), the patient is categorized as having hyperferritinemia. Iron chelators such as deferiprone, deferirox, and deferoxamine are currently FDA approved to treat iron overload. The inflammation cascade and poor prognosis of COVID-19 may be attributed to high ferritin levels. Critically ill patients can benefit from deferasirox, an iron chelator administered orally at 20–40 mgkg(−1) once daily, as well as intravenous deferoxamine at 1000 mg initially followed by 500 mg every 4 to 12 h. It can be combined with monoclonal antibodies, antioxidants, corticosteroids, and lactoferrin to make iron chelation therapy effective for COVID-19 victims. In this article, we analyze the antiviral and antifibrotic activity of iron chelators, thereby promoting iron depletion therapy as a potentially innovative treatment strategy for COVID-19. |
format | Online Article Text |
id | pubmed-8666385 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-86663852021-12-14 Therapeutic potential of induced iron depletion using iron chelators in Covid-19 Poonkuzhi Naseef, Punnoth Elayadeth-Meethal, Muhammed Mohammed Salim, K.T. Anjana, A Muhas, C Abdul Vajid, K. Saheer Kuruniyan, Mohamed Saudi J Biol Sci Review Ferritin, which includes twenty-four light and heavy chains in varying proportions in different tissues, is primarily responsible for maintaining the body's iron metabolism. Its normal value is between 10 and 200 ngmL(−1) in men and between 30 and 300 ngmL(−1) in women. Iron is delivered to the tissue via them, and they act as immunomodulators, signaling molecules, and inflammatory markers. When ferritin level exceeds 1000 µgL(-1), the patient is categorized as having hyperferritinemia. Iron chelators such as deferiprone, deferirox, and deferoxamine are currently FDA approved to treat iron overload. The inflammation cascade and poor prognosis of COVID-19 may be attributed to high ferritin levels. Critically ill patients can benefit from deferasirox, an iron chelator administered orally at 20–40 mgkg(−1) once daily, as well as intravenous deferoxamine at 1000 mg initially followed by 500 mg every 4 to 12 h. It can be combined with monoclonal antibodies, antioxidants, corticosteroids, and lactoferrin to make iron chelation therapy effective for COVID-19 victims. In this article, we analyze the antiviral and antifibrotic activity of iron chelators, thereby promoting iron depletion therapy as a potentially innovative treatment strategy for COVID-19. Elsevier 2022-04 2021-12-13 /pmc/articles/PMC8666385/ /pubmed/34924800 http://dx.doi.org/10.1016/j.sjbs.2021.11.061 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Poonkuzhi Naseef, Punnoth Elayadeth-Meethal, Muhammed Mohammed Salim, K.T. Anjana, A Muhas, C Abdul Vajid, K. Saheer Kuruniyan, Mohamed Therapeutic potential of induced iron depletion using iron chelators in Covid-19 |
title | Therapeutic potential of induced iron depletion using iron chelators in Covid-19 |
title_full | Therapeutic potential of induced iron depletion using iron chelators in Covid-19 |
title_fullStr | Therapeutic potential of induced iron depletion using iron chelators in Covid-19 |
title_full_unstemmed | Therapeutic potential of induced iron depletion using iron chelators in Covid-19 |
title_short | Therapeutic potential of induced iron depletion using iron chelators in Covid-19 |
title_sort | therapeutic potential of induced iron depletion using iron chelators in covid-19 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666385/ https://www.ncbi.nlm.nih.gov/pubmed/34924800 http://dx.doi.org/10.1016/j.sjbs.2021.11.061 |
work_keys_str_mv | AT poonkuzhinaseefpunnoth therapeuticpotentialofinducedirondepletionusingironchelatorsincovid19 AT elayadethmeethalmuhammed therapeuticpotentialofinducedirondepletionusingironchelatorsincovid19 AT mohammedsalimkt therapeuticpotentialofinducedirondepletionusingironchelatorsincovid19 AT anjanaa therapeuticpotentialofinducedirondepletionusingironchelatorsincovid19 AT muhasc therapeuticpotentialofinducedirondepletionusingironchelatorsincovid19 AT abdulvajidk therapeuticpotentialofinducedirondepletionusingironchelatorsincovid19 AT saheerkuruniyanmohamed therapeuticpotentialofinducedirondepletionusingironchelatorsincovid19 |